• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

镥-177 治疗期间辐射安全的临床最佳实践

Clinical Best Practices for Radiation Safety During Lutetium-177 Therapy.

机构信息

McMaster University Health Physics Department, Hamilton, ON, Canada.

Fox Chase Cancer Center, Philadelphia, PA.

出版信息

Health Phys. 2023 Feb 1;124(2):139-146. doi: 10.1097/HP.0000000000001644. Epub 2022 Dec 10.

DOI:10.1097/HP.0000000000001644
PMID:36508552
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9803381/
Abstract

IMPORTANCE

177 Lu therapy as part of theranostic treatment for cancer is expanding but it can be a challenge for sites with limited radiation protection staff to implement the radiation safety program required for therapeutic nuclear medicine.

OBJECTIVE

To increase the adoption of 177 Lu therapy, especially in smaller centers and clinics, by providing a collection of radiation safety best practices and operational experience. To provide a resource for radiation safety officers supporting the implementation of a 177 Lu therapy program.

METHODS

A panel of 11 radiation safety professionals representing sites across Canada and the United States with experience delivering 177 Lu therapy was assembled and discussed their responses to a list of questions focused on the following radiation safety topics: facility layout and design; radiation safety program; and drug management and patient care.

RESULTS

A comprehensive set of best practice guidelines for clinical radiation safety during 177 Lu therapy has been developed based on the collective operational experience of a group of radiation safety professionals. Significant findings included that 177 Lu therapy is often safely administered in unshielded rooms, that staff radiation exposure associated with 177 Lu therapy is minimal relative to other nuclear medicine programs, and that some relatively simple preparation in advance including papering of common surfaces and planning for incontinence can effectively control contamination during therapy.

CONCLUSION

The guidance contained in this paper will assist radiation safety professionals in the implementation of safe, effective 177 Lu therapy programs, even at smaller sites with limited to no experience in therapeutic nuclear medicine.

摘要

重要性

作为癌症治疗的诊断与治疗的一部分,177Lu 治疗正在不断发展,但对于辐射防护人员有限的站点来说,实施治疗核医学所需的辐射安全计划可能是一个挑战。

目的

通过提供一系列辐射安全最佳实践和运营经验,增加 177Lu 治疗的采用,特别是在较小的中心和诊所。为支持 177Lu 治疗计划实施的辐射安全官员提供资源。

方法

组建了一个由 11 名代表加拿大和美国各地具有 177Lu 治疗经验的站点的辐射安全专业人员组成的小组,并讨论了他们对一系列问题的回答,这些问题集中在以下辐射安全主题上:设施布局和设计;辐射安全计划;以及药物管理和患者护理。

结果

根据一组辐射安全专业人员的集体运营经验,制定了一套全面的 177Lu 治疗期间临床辐射安全最佳实践指南。主要发现包括:177Lu 治疗通常可以在无屏蔽的房间内安全进行;与其他核医学计划相比,与 177Lu 治疗相关的工作人员辐射暴露量很小;一些相对简单的提前准备,包括常见表面的裱糊和失禁计划,可以有效地控制治疗期间的污染。

结论

本文中的指南将帮助辐射安全专业人员实施安全有效的 177Lu 治疗计划,即使是在治疗核医学经验有限或没有经验的较小站点也是如此。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e72/9803381/d0ac00603743/hpj-124-139-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e72/9803381/17803043317a/hpj-124-139-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e72/9803381/4cf3398559dc/hpj-124-139-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e72/9803381/d0ac00603743/hpj-124-139-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e72/9803381/17803043317a/hpj-124-139-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e72/9803381/4cf3398559dc/hpj-124-139-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e72/9803381/d0ac00603743/hpj-124-139-g003.jpg

相似文献

1
Clinical Best Practices for Radiation Safety During Lutetium-177 Therapy.镥-177 治疗期间辐射安全的临床最佳实践
Health Phys. 2023 Feb 1;124(2):139-146. doi: 10.1097/HP.0000000000001644. Epub 2022 Dec 10.
2
EANM procedure guidelines for radionuclide therapy with Lu-labelled PSMA-ligands (Lu-PSMA-RLT).EANM 程序指南:镥[177Lu]标记的 PSMA 配体(Lu-PSMA-RLT)放射性核素治疗。
Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2536-2544. doi: 10.1007/s00259-019-04485-3. Epub 2019 Aug 22.
3
Evolving Important Role of Lutetium-177 for Therapeutic Nuclear Medicine.镥-177在治疗性核医学中日益重要的作用。
Curr Radiopharm. 2015;8(2):78-85. doi: 10.2174/1874471008666150312155959.
4
Quantifying public radiation exposure related to lutetium-177 octreotate therapy for the development of a safe outpatient treatment protocol.量化与镥-177奥曲肽治疗相关的公众辐射暴露,以制定安全的门诊治疗方案。
Nucl Med Commun. 2015 Feb;36(2):129-34. doi: 10.1097/MNM.0000000000000232.
5
Radiation Safety Observations Associated with 177Lu Dotatate Patients.与 177Lu 镥 DOTATATE 患者相关的辐射安全观察。
Health Phys. 2019 Dec;117(6):680-687. doi: 10.1097/HP.0000000000001122.
6
Radiation safety of current European practices of therapeutic nuclear medicine: survey results from 20 HERCA countries.当前欧洲治疗性核医学实践的辐射安全:来自20个HERCA国家的调查结果。
J Radiol Prot. 2023 Jan 30;43(1). doi: 10.1088/1361-6498/acafef.
7
Initial experience and lessons learned with implementing Lutetium-177-dotatate radiopharmaceutical therapy in a radiation oncology-based program.在基于放射肿瘤学的项目中实施镥-177 替曲肽放射性药物治疗的初步经验和教训。
Brachytherapy. 2021 Jan-Feb;20(1):237-247. doi: 10.1016/j.brachy.2020.07.004. Epub 2020 Aug 17.
8
Leveraging Radiopharmaceutical Programmatic Collaboration for Management of Pretherapy and On-treatment Urinary Incontinence.利用放射性药物项目合作管理治疗前和治疗期间的尿失禁。
Health Phys. 2023 Oct 1;125(4):316-319. doi: 10.1097/HP.0000000000001721. Epub 2023 Aug 8.
9
Radiation safety of outpatient 177Lu-octreotate radiopeptide therapy of neuroendocrine tumors.门诊177Lu-奥曲肽放射性肽治疗神经内分泌肿瘤的辐射安全性
Ann Nucl Med. 2014 Jul;28(6):531-9. doi: 10.1007/s12149-014-0843-8. Epub 2014 Apr 1.
10
A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.镥-177-前列腺特异性膜抗原放射性核素治疗在转移性去势抵抗性前列腺癌老年患者中的安全性和疗效的回顾性分析。
Oncologist. 2020 Sep;25(9):787-792. doi: 10.1634/theoncologist.2020-0100. Epub 2020 Jun 10.

引用本文的文献

1
Dealing with radiation risks in systemic cancer treatment: Perspectives of practitioners and patients in French hospitals.应对系统性癌症治疗中的辐射风险:法国医院从业者与患者的观点
PLoS One. 2025 Mar 6;20(3):e0316998. doi: 10.1371/journal.pone.0316998. eCollection 2025.
2
Radiation Safety Assessment of 177Lu-DOTATATE Intra-arterial Peptide Receptor Therapy (PRRT).177Lu-奥曲肽动脉内肽受体放射性核素治疗(PRRT)的辐射安全评估
Indian J Nucl Med. 2024 Jul-Aug;39(4):254-258. doi: 10.4103/ijnm.ijnm_88_23. Epub 2024 Nov 18.
3
Clinical Best Practices for Radiation Safety During an Alpha DaRT Treatment.
阿尔法靶向放射治疗期间辐射安全的临床最佳实践
Health Phys. 2025 Jun 1;128(6):536-541. doi: 10.1097/HP.0000000000001928. Epub 2024 Nov 20.
4
Enhancing safety: Multi-institutional FMEA and FTA on -based radio-pharmaceutical therapy.提高安全性:基于[具体内容缺失]的放射性药物治疗的多机构失效模式与效应分析及故障树分析
J Appl Clin Med Phys. 2025 Jan;26(1):e14550. doi: 10.1002/acm2.14550. Epub 2024 Nov 13.
5
Precision radiation opens a new window on cancer therapy.精准放疗为癌症治疗打开了一扇新窗口。
Nat Biotechnol. 2024 Jul;42(7):1003-1008. doi: 10.1038/s41587-024-02295-z.
6
Radiation exposure assessment of nuclear medicine staff administering [Lu]Lu-DOTA-TATE with active and passive dosimetry.使用主动和被动剂量测定法对施用[镥]镥-多柔比星的核医学工作人员进行辐射暴露评估。
EJNMMI Phys. 2023 Nov 14;10(1):70. doi: 10.1186/s40658-023-00592-1.
7
Leveraging Radiopharmaceutical Programmatic Collaboration for Management of Pretherapy and On-treatment Urinary Incontinence.利用放射性药物项目合作管理治疗前和治疗期间的尿失禁。
Health Phys. 2023 Oct 1;125(4):316-319. doi: 10.1097/HP.0000000000001721. Epub 2023 Aug 8.
8
Challenges of Deep Learning in Cancers.深度学习在癌症领域面临的挑战。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231173495. doi: 10.1177/15330338231173495.